First-line immunotherapy for advanced hepatocellular carcinoma: a network meta-analysis of randomized trials with overall and HBV/HCV-stratified efficacy and safety.

Front Immunol · 2026 · PMC13215822 · PMID 42220514

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In contrast, the PFS improvement in the NBNC subgroup did not reach statistical significance (HR = 0.74, 95% CI 0.52-1.06).

also in 111,027 other papers

borderline significantno p-value reported

In non-Asia-enriched trials, the pooled HR was 0.82 (95% CI 0.67-1.00; I2=51%), suggesting a borderline significant survival advantage.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.